Filoviruses—such as Ebola and Marburg viruses—can cause hemorrhagic fevers with up to 90% lethality. Not only that, but there are very few tools (vaccines or drugs) to combat them. Now, scientists at ...
Late-breaking oral presentation highlights interim Phase 1b data reported earlier this year for two cohorts in participants with recurrent ...
– ABI-5366 is currently being evaluated in ongoing Phase 1b clinical trial with interim proof-of-concept data expected in fall 2025 – SOUTH SAN FRANCISCO, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- ...
Jamil Saad, Ph.D. Jamil Saad, Ph.D., professor in the Department of Microbiology, is the latest winner of the Heersink School of Medicine’s Featured Discovery. This initiative celebrates important ...
RNA viruses are renowned for their elegant structure and finely tuned self‐assembly processes, which are critical both for viral life cycles and for potential applications in nanotechnology and ...
– Interim proof-of-concept Phase 1b data in participants with recurrent genital herpes expected for both candidates in fall 2025 – SOUTH SAN FRANCISCO, Calif., July 26, 2025 (GLOBE NEWSWIRE) -- ...
Assembly Biosciences (ASMB) announced that interim Phase 1b clinical data for its long-acting herpes simplex virus helicase-primase inhibitor ...
– Late-breaker poster highlights preclinical profile of ABI-6250, currently in Phase 1a with data anticipated in Q3 2025 – – Second poster describes in vitro studies of effects on viral infection ...
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback